Navitoclax (ABT-263)

Catalog No.S1001

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Cited by 43 Publications

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )
Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )
Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )
Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

13 Customer Reviews

KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.
ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.
Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.
Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.
PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.
Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

(A) In vitro generated Mcl-1-deleted Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM. p185+ Arf-/- cells serve as a control. (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or (E) IM or (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

Navitoclax (ABT-263) purchased from Selleck.
Human Ph+ cell lines: (A) OP-1 Ph+ B-ALL (B) TOM1 Ph+ B-ALL and (C) BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL. For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	M2jMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzETWM2OD1yLkCwOlY6KM7:TR?=	MmLMV2FPT0WU
MV-4-11	NV3HV3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13J[2lEPTB;MD6wNVU5PiEQvF2=	NXnYfmpkW0GQR1XS
NKM-1	NYTMT4VnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPtSY1KSzVyPUCuNFE3QTlizszN	Mlz5V2FPT0WU
ML-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\v[2lEPTB;MD6wNVk5OyEQvF2=	NYq0VXk5W0GQR1XS
BV-173	NXKyfIRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjobZE1UUN3ME2wMlAzOzF2IN88US=>	Mm\ZV2FPT0WU
RS4-11	M1TOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInkSlhKSzVyPUCuNFI2QDdizszN	Mn:3V2FPT0WU
HL-60	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHCTWM2OD1yLkCyPVA5KM7:TR?=	MY\TRW5ITVJ?
KY821	Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;GZoVGUUN3ME2wMlAzQTd3IN88US=>	M3LHOnNCVkeHUh?=
ECC10	NVnhTHJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTkbpZKSzVyPUCuNFM4QTJizszN	MkPuV2FPT0WU
NCI-H720	NGXk[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrHTWM2OD1yLkC0NFEyKM7:TR?=	MYXTRW5ITVJ?
QIMR-WIL	NWfnTWJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMESyPFch\|ryP	NW\GfGdqW0GQR1XS
KG-1	NW[4SlVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwMES0PFYh\|ryP	NYT1VYV7W0GQR1XS
TGW	NEXiOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnlWmVxUUN3ME2wMlA1PjN\|IN88US=>	M4nDUXNCVkeHUh?=
ATN-1	MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LxOmlEPTB;MD6wOFc{OyEQvF2=	NX23fXdTW0GQR1XS
RH-18	M{j5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDEOIxKSzVyPUCuNFYxPDhizszN	MmrrV2FPT0WU
EW-18	M2PB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jjUmlEPTB;MD6wOlg1OSEQvF2=	MYTTRW5ITVJ?
NB17	NFzS[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLkZYJHUUN3ME2wMlA4OTJ2IN88US=>	M1rjSHNCVkeHUh?=
SK-NEP-1	NYPoNYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLxTWM2OD1yLkC3NlE{KM7:TR?=	M4jlTHNCVkeHUh?=
P12-ICHIKAWA	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnqeHNVUUN3ME2wMlA4Pzd6IN88US=>	NGrmdIJUSU6JRWK=
KARPAS-45	M{XBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnHfHJKSzVyPUCuNFc5OTVizszN	M2jxdHNCVkeHUh?=
EW-3	M2XUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMEiwOVMh\|ryP	M2nvNXNCVkeHUh?=
NB13	M4i5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMEiyNFMh\|ryP	M4jPUXNCVkeHUh?=
NCI-H209	M3y5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7GTGlKSzVyPUCuNFg4ODRizszN	NVTiNFlxW0GQR1XS
NCI-H1092	NWnJSmlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMUCyO\|Uh\|ryP	M3Lsb3NCVkeHUh?=
NH-12	NWX6RVZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[0cmlEPTB;MD6xNFc1PCEQvF2=	MXzTRW5ITVJ?
697	M3zPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XUSGlEPTB;MD6xNFg{QSEQvF2=	NGj2UnNUSU6JRWK=
KE-37	MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXFTWM2OD1yLkGxN\|ch\|ryP	MVLTRW5ITVJ?
MOLT-4	M173XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMUWxOlkh\|ryP	NHrJRlBUSU6JRWK=
CHP-134	NHrUTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMU[zNFYh\|ryP	M1fJTXNCVkeHUh?=
D-283MED	NV[3XZYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjjd4FkUUN3ME2wMlE4Pjh4IN88US=>	Mni1V2FPT0WU
LU-135	NUHId3J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPBc2FKSzVyPUCuNVg2PTJizszN	MVLTRW5ITVJ?
LU-134-A	MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzyTlhKSzVyPUCuNVg3PzFizszN	NVj3T2JGW0GQR1XS
EM-2	NIK5OZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGiyTFRKSzVyPUCuNVk6OThizszN	MXPTRW5ITVJ?
LU-139	NWL5PVJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUmyelFuUUN3ME2wMlIxPDl6IN88US=>	MlnKV2FPT0WU
ALL-PO	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfPRldKSzVyPUCuNlE6QDhizszN	NFzlUmxUSU6JRWK=
NB12	NVv6TnNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HmbmlEPTB;MD6yN\|EyPSEQvF2=	NULTdHhuW0GQR1XS
KP-N-YN	NU\ofWY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHMNndKSzVyPUCuNlM2PzNizszN	MYHTRW5ITVJ?
BEN	NFW2R5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3T6dmlEPTB;MD6yN\|k3QCEQvF2=	MVPTRW5ITVJ?
HCC1569	NEK2dpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nIWWlEPTB;MD6yOVExPiEQvF2=	MlK2V2FPT0WU
HuO9	NULM[3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HBd2lEPTB;MD6yOlcyPSEQvF2=	NWDPeZJ6W0GQR1XS
WM-115	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrrSJlKSzVyPUCuNlc4OzhizszN	MVvTRW5ITVJ?
CCRF-CEM	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwM{O1Nlkh\|ryP	MYfTRW5ITVJ?
IST-SL1	NGfWUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\0V3BuUUN3ME2wMlM2OzR\|IN88US=>	NETpOXZUSU6JRWK=
BE-13	MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrac3AxUUN3ME2wMlM3PDV7IN88US=>	MmDXV2FPT0WU
COR-L88	NFjSXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;PTWM2OD1yLkO2OVQh\|ryP	NGHOd2lUSU6JRWK=
DOHH-2	M1zvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWX6NJlIUUN3ME2wMlQyODJ\|IN88US=>	NUjRbIY2W0GQR1XS
A704	NXTybHFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlryTWM2OD1yLkSyOlch\|ryP	NHP0XmJUSU6JRWK=
KNS-81-FD	M1vzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwNESwNVch\|ryP	MX7TRW5ITVJ?
RPMI-8226	Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\sfZpYUUN3ME2wMlQ2PjV{IN88US=>	MXTTRW5ITVJ?
TGBC24TKB	MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nhSWlEPTB;MD60OVc4QCEQvF2=	Mn\yV2FPT0WU
NCI-H1304	NWPkXlQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfOTVNKSzVyPUCuOFYyPTdizszN	MYrTRW5ITVJ?
MOLT-13	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjmSnBlUUN3ME2wMlQ3PjF\|IN88US=>	MX;TRW5ITVJ?
EW-22	M3Pqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nKdmlEPTB;MD60OlY4OSEQvF2=	NV\EcFNYW0GQR1XS
MS-1	Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjab\|dKSzVyPUCuOFY6OzNizszN	M4Tw[3NCVkeHUh?=
RMG-I	NFK2VmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\2XGlEPTB;MD60PVQ3PCEQvF2=	NX23c\|hWW0GQR1XS
NTERA-S-cl-D1	M16wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPPS3BKSzVyPUCuOVAxOTlizszN	MkfFV2FPT0WU
NCI-H1048	NH;HOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHJO5VqUUN3ME2wMlUxQTV\|IN88US=>	MWrTRW5ITVJ?
SW1417	M3rtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\DTJh2UUN3ME2wMlU2PDN6IN88US=>	MoDHV2FPT0WU
DB	M2e3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTFTWM2OD1yLkW3NFgh\|ryP	Mn3GV2FPT0WU
MEG-01	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwNUizNkDPxE1?	NXrEb\|B4W0GQR1XS
EW-13	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL3U4t3UUN3ME2wMlU5OzRzIN88US=>	NW[wT4ZFW0GQR1XS
LAMA-84	NHvsXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfVbpNFUUN3ME2wMlU6OjB5IN88US=>	NGfRbZRUSU6JRWK=
J-RT3-T3-5	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPmZ2NKSzVyPUCuOlA5ODhizszN	MY\TRW5ITVJ?
MOLT-16	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjyfY9KSzVyPUCuOlUzPjRizszN	MmfCV2FPT0WU
DU-4475	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDzUFJyUUN3ME2wMlY2PDJ5IN88US=>	M2TaSnNCVkeHUh?=
HAL-01	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXkfYRKSzVyPUCuO\|I2PDlizszN	MUfTRW5ITVJ?
RD	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTCTWM2OD1yLke1PFk6KM7:TR?=	MmD4V2FPT0WU
OAW-28	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHUU5ZKSzVyPUCuO\|g{PyEQvF2=	MWLTRW5ITVJ?
HCC38	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXFZ2FKSzVyPUCuPFAyQSEQvF2=	M3G4N3NCVkeHUh?=
NMC-G1	NGTkSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlv3TWM2OD1yLkixNVIyKM7:TR?=	NH6x[HdUSU6JRWK=
EW-16	Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jnW2lEPTB;MD64NVMzQCEQvF2=	NGP2R4VUSU6JRWK=
DU-145	MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwOEm5NlMh\|ryP	NFnrV\|lUSU6JRWK=
HPAF-II	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwOUK2Nlgh\|ryP	NXHueGROW0GQR1XS
A427	NUnxOFVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDBRVJKSzVyPUCuPVMxOjJizszN	NU\QcHg{W0GQR1XS
PA-1	NGPUTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwOUW2OFIh\|ryP	NETifJJUSU6JRWK=
OAW-42	NH21fJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfzXXdKSzVyPUCuPVYyPDZizszN	M3jYWHNCVkeHUh?=
L-428	M3\XXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4juUmlEPTB;MT6wNVI2KM7:TR?=	MUTTRW5ITVJ?
COLO-824	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\hXoxKSzVyPUGuNFE4ODhizszN	NFzVTnNUSU6JRWK=
P30-OHK	M4Die2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHaTWM2OD1zLkC0Olg5KM7:TR?=	NUHNWphJW0GQR1XS
NCI-H2170	MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfyfHdKSzVyPUGuNFYzOyEQvF2=	M1nhd3NCVkeHUh?=
HCC2998	M3K4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTFwMEexN\|Uh\|ryP	MmW5V2FPT0WU
NB14	NUL4eGh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;vTWM2OD1zLkGzO\|Q5KM7:TR?=	NEjsdFhUSU6JRWK=
TGBC1TKB	MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEe0Z\|BKSzVyPUGuNVQyPTJizszN	NGK2RlVUSU6JRWK=
KP-N-YS	NVL6U2pjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zZZ2lEPTB;MT6xOlI{PiEQvF2=	NWfURXpGW0GQR1XS
CAL-120	M3jtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\nTWM2OD1zLkG2OFI6KM7:TR?=	M1S3WXNCVkeHUh?=
SBC-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTFwMUmwOVMh\|ryP	NFXX[pNUSU6JRWK=
C32	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHCTWM2OD1zLkG5NFg5KM7:TR?=	MWjTRW5ITVJ?
HCC2157	M{joemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTvXGUyUUN3ME2xMlE6PDl2IN88US=>	M1HB[3NCVkeHUh?=
COLO-792	NYnVTGhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTFwMkCwO\|Eh\|ryP	NHPsZVJUSU6JRWK=
ES7	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;4fY1KSzVyPUGuNlc6PTFizszN	MmXLV2FPT0WU
HEL	MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLM[YhKSzVyPUGuN\|ExOjlizszN	MYPTRW5ITVJ?
ES4	NVG4Wo1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTFwM{S5PVgh\|ryP	NGXsOmRUSU6JRWK=
NCI-SNU-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmf4TWM2OD1zLkO2OVU2KM7:TR?=	M13rVXNCVkeHUh?=
MDA-MB-415	MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnPTWM2OD1zLkO4PFUh\|ryP	MYHTRW5ITVJ?
NCI-H2342	NEXlXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGn6UWNKSzVyPUGuOFAzPjlizszN	MYPTRW5ITVJ?
NB69	NVrKNFVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PMSWlEPTB;MT60OlI4OSEQvF2=	MlzQV2FPT0WU
D-247MG	MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHETWM2OD1zLkWxNVIzKM7:TR?=	M2XRfXNCVkeHUh?=
SCC-4	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYq5W\|ZRUUN3ME2xMlU6QDh5IN88US=>	MmnJV2FPT0WU
HuH-7	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;yOGlEPTB;MT62O\|I6OyEQvF2=	NWT5W5lLW0GQR1XS
A388	NET5N\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLTUFF7UUN3ME2xMlY5PzJ2IN88US=>	M{jrcXNCVkeHUh?=
Calu-3	MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjIRopQUUN3ME2xMlcxPjl5IN88US=>	M2DUd3NCVkeHUh?=
NCI-H1648	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYriWXg4UUN3ME2xMlcyPDF6IN88US=>	MVPTRW5ITVJ?
NCI-H2052	NI[zXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LOSWlEPTB;MT63NlIxOSEQvF2=	NUTjfYZMW0GQR1XS
Ramos-2G6-4C10	M1rMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljpTWM2OD1zLkezOlU3KM7:TR?=	Mn3OV2FPT0WU
DEL	M3\LW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrLTWM2OD1zLke0OlkzKM7:TR?=	NHLZWHZUSU6JRWK=
SNU-423	MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTDTWM2OD1zLke4NVU4KM7:TR?=	NUf4T4FFW0GQR1XS
COR-L23	M1Hj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF2zR\|BKSzVyPUGuO\|k5PzRizszN	NVGwbYs6W0GQR1XS
OMC-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33vNmlEPTB;MT64OlAyPiEQvF2=	NHPGVI9USU6JRWK=
EW-11	Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37MemlEPTB;MT65OVY2PyEQvF2=	NUj1WWs5W0GQR1XS
HSC-3	NHm3OXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLxNXpQUUN3ME2xMlk3OzZ3IN88US=>	MYXTRW5ITVJ?
MLMA	Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:3TWM2OD1zLkm2Olc4KM7:TR?=	NX:yb25sW0GQR1XS
RCM-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnPXGR4UUN3ME2yMlAxOzl7IN88US=>	M2TzPXNCVkeHUh?=
MFE-280	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\U[VJwUUN3ME2yMlAzQDR6IN88US=>	M4jxWXNCVkeHUh?=
ES8	NFLGPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLCSotMUUN3ME2yMlI2PDdzIN88US=>	MWTTRW5ITVJ?
TE-11	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHTUmF{UUN3ME2yMlI6PDd\|IN88US=>	NXjrcnQ3W0GQR1XS
HuO-3N1	NHLndJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1iyVmlEPTB;Mj60PFc5KM7:TR?=	NXWxW3lIW0GQR1XS
MHH-NB-11	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTJwNUGxOVgh\|ryP	NGTWTGNUSU6JRWK=
TGBC11TKB	M3Owfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIW0R2dKSzVyPUKuOVc3QDFizszN	M1XHfXNCVkeHUh?=
HOP-92	MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjPTWM2OD1{LkW4O\|Q{KM7:TR?=	MY\TRW5ITVJ?
IGR-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGGzcJdKSzVyPUKuOlIxOzVizszN	Mli3V2FPT0WU
GOTO	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTJwNkWzO\|ch\|ryP	M1PQcXNCVkeHUh?=
NCI-H1650	M3GxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:yTWM2OD1{LkeyNlE2KM7:TR?=	MXLTRW5ITVJ?
NCI-H1581	MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGKwVWNKSzVyPUKuO\|k3QDFizszN	NGrieWFUSU6JRWK=
NCI-H2405	NX[5Npl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFL6WXJKSzVyPUKuPFI4QDJizszN	Mn\JV2FPT0WU
U-118-MG	NG[3dmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFiwS\|lKSzVyPUKuPVY1QTFizszN	Mnj3V2FPT0WU
DoTc2-4510	M{DINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlv0TWM2OD1\|LkCxOFE4KM7:TR?=	MXfTRW5ITVJ?
NCI-H596	M1ewVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfYeYpQUUN3ME2zMlA1QTl5IN88US=>	M1;NbnNCVkeHUh?=
MPP-89	M3rwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fnS2lEPTB;Mz6wOVY3PiEQvF2=	NWrod5RjW0GQR1XS
GCIY	M4nqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUX2PXFoUUN3ME2zMlIxPDlzIN88US=>	M1\ie3NCVkeHUh?=
SW626	Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S3[2lEPTB;Mz6yOFU1OyEQvF2=	NH36ZVhUSU6JRWK=
OCI-AML2	NI\qZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHTS2NKSzVyPUOuN\|EzPzJizszN	MV7TRW5ITVJ?
NBsusSR	MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDjTWM2OD1\|LkO0PVM5KM7:TR?=	M2fyS3NCVkeHUh?=
AN3-CA	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvOTm1KSzVyPUOuOFQzOzhizszN	NYjFcmE2W0GQR1XS
EFM-19	NVvEfJJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2n1SGlEPTB;Mz60PFM{QSEQvF2=	MlfGV2FPT0WU
RVH-421	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTNwNU[4O\|ch\|ryP	MYTTRW5ITVJ?
5637	NES3bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnkd3dKSzVyPUOuOlEyODNizszN	NIfve4dUSU6JRWK=
PANC-08-13	NYXDZW5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTNwNkO0O\|Ih\|ryP	NHqyfYdUSU6JRWK=
H9	MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLGSYtRUUN3ME2zMlY4OTR2IN88US=>	M1i3dHNCVkeHUh?=
KARPAS-299	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TPVmlEPTB;Mz62O\|M3OSEQvF2=	M{Lhc3NCVkeHUh?=
TE-5	NVrwV5M{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\3TWM2OD1\|LkewO\|A6KM7:TR?=	M32z[XNCVkeHUh?=
NOS-1	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\STWM2OD1\|Lke5PFM1KM7:TR?=	NI\ZXIVUSU6JRWK=
HH	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTNwOEO4Olgh\|ryP	MljVV2FPT0WU
769-P	NFPwN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3NPGY6UUN3ME2zMlg6PTFizszN	MmH0V2FPT0WU
CHP-212	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUP6dIxiUUN3ME2zMlkzPTR7IN88US=>	NWPTNFhwW0GQR1XS
NCI-H82	NV21PWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPLTWM2OD1\|Lkm1PVM3KM7:TR?=	MWHTRW5ITVJ?
Mo-T	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTRwMESzNVIh\|ryP	MkLuV2FPT0WU
BB65-RCC	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHHW3RvUUN3ME20MlA1Ozl7IN88US=>	MULTRW5ITVJ?
SW1990	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDETWM2OD12LkC1PVA5KM7:TR?=	NV7xenM1W0GQR1XS
LK-2	NF\lUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIm4OWpKSzVyPUSuNVEzQTNizszN	MYXTRW5ITVJ?
ES5	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;PN4lTUUN3ME20MlE{QTh3IN88US=>	NHvzfnlUSU6JRWK=
JVM-3	MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPGZW9KSzVyPUSuNVgzOjJizszN	M1:4TnNCVkeHUh?=
RPMI-7951	NGTUTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Hsb2lEPTB;ND6yNlQyOyEQvF2=	M4fBS3NCVkeHUh?=
Calu-6	NHGzdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTRwMke4PFEh\|ryP	M3XJc3NCVkeHUh?=
LC-2-ad	M17YbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE[zR49KSzVyPUSuNlk2PjhizszN	M4TOeHNCVkeHUh?=
SW954	NYLaXnVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTRwMkm2OkDPxE1?	Mn7pV2FPT0WU
H-EMC-SS	NVvTXol5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\sc3dKSzVyPUSuN\|E5OzFizszN	M1zIcXNCVkeHUh?=
ES3	NGXpZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELu[HNKSzVyPUSuN\|U1PDFizszN	M3TMWHNCVkeHUh?=
no-11	Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvpTWM2OD12LkO1OVU1KM7:TR?=	M4rLcnNCVkeHUh?=
LAN-6	NWfVUWpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn6WWdKSzVyPUSuOFUyQDlizszN	MY\TRW5ITVJ?
FTC-133	NW\1XYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;6TJg4UUN3ME20MlU{QTVizszN	NWrKUlJEW0GQR1XS
8505C	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Xye2lEPTB;ND61OFI{KM7:TR?=	M4eyXHNCVkeHUh?=
SW620	NGDYW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrpTWM2OD12LkW3NFU4KM7:TR?=	M2LRTXNCVkeHUh?=
BCPAP	NHHj[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfx[Gt1UUN3ME20MlY{PDhzIN88US=>	M1TZXnNCVkeHUh?=
SK-LU-1	MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4e1RmlEPTB;ND62OlA5QSEQvF2=	MUTTRW5ITVJ?
NCI-H1623	NYjCTY5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTRwN{CyNlgh\|ryP	MVfTRW5ITVJ?
C2BBe1	NEHaO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDCTWM2OD12Lke0NFA5KM7:TR?=	MX\TRW5ITVJ?
GP5d	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL4N3ZKSzVyPUSuO\|g{QDhizszN	M{nGdnNCVkeHUh?=
NB6	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL6XJhKSzVyPUSuPFYzODRizszN	NHrL[HpUSU6JRWK=
MDA-MB-157	NYfnPGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHJWZBKSzVyPUSuPFg4PiEQvF2=	NU\NZXdwW0GQR1XS
UMC-11	MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\RTWM2OD12Lki4PVY1KM7:TR?=	M2rQWHNCVkeHUh?=
HCC1419	NG[xUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3ROIx5UUN3ME20MlkxODZ\|IN88US=>	NGnMUWRUSU6JRWK=
NCI-H2029	Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFT3d\|BKSzVyPUSuPVQyQDVizszN	M{Dsd3NCVkeHUh?=
LXF-289	NYLtdIRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzxXHlKSzVyPUWuNFM4OTlizszN	MU\TRW5ITVJ?
KINGS-1	M4TrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYraXFI2UUN3ME21MlA4PzR2IN88US=>	NEOxUopUSU6JRWK=
HD-MY-Z	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTlbJZKSzVyPUWuNlM6PjlizszN	M1rYRXNCVkeHUh?=
ESS-1	NITLZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfLSY5QUUN3ME21MlI2PTl5IN88US=>	MVXTRW5ITVJ?
GI-1	MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTVwMke5NlYh\|ryP	NIq1XoJUSU6JRWK=
RPMI-2650	NHLS[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXJTWM2OD13LkO2NVYh\|ryP	MVPTRW5ITVJ?
IA-LM	NXnuUZB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3GTWM2OD13LkO5PFcyKM7:TR?=	NEPHbY1USU6JRWK=
KP-4	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLtTWM2OD13LkS2N\|M1KM7:TR?=	NIPWc\|VUSU6JRWK=
G-402	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLTTWM2OD13LkWxPFY2KM7:TR?=	M3vWWHNCVkeHUh?=
OS-RC-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XOUGlEPTB;NT61NlYxPCEQvF2=	NV\WUWg1W0GQR1XS
NCI-H1155	MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DoNGlEPTB;NT61OFk2PSEQvF2=	MYTTRW5ITVJ?
OE19	NGPLcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfDXIdKSzVyPUWuOlg3OjRizszN	MkjvV2FPT0WU
U-2-OS	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\U[Y9KSzVyPUWuPFkxOTNizszN	MkDjV2FPT0WU
SCC-15	M4PaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXq1[ot3UUN3ME21Mlk{PjZ{IN88US=>	M3O0V3NCVkeHUh?=
NCI-H630	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELSS2pKSzVyPUWuPVk1ODRizszN	M1ztenNCVkeHUh?=
PFSK-1	NVjJR4ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTZwMEWyOVkh\|ryP	M1frfnNCVkeHUh?=
NCI-H1770	NHT4TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzxNJBxUUN3ME22MlIxQDd2IN88US=>	NH7LRWZUSU6JRWK=
SK-MEL-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjhWm5KSzVyPU[uOFI6OTVizszN	NEnEeWdUSU6JRWK=
LB1047-RCC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFH2OG5KSzVyPU[uOFc3OjVizszN	NVz0WGNRW0GQR1XS
NCI-H446	NWDVVWsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknRTWM2OD14Lk[yPVI2KM7:TR?=	NFTDWFdUSU6JRWK=
SW780	M{H2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTZwN{CxPFUh\|ryP	NGHsVZhUSU6JRWK=
NEC8	Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTZwN{[2N{DPxE1?	NXuyclRQW0GQR1XS
NOMO-1	NYnDOmtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2K1UWlEPTB;Nj63PFEyOSEQvF2=	NEThN5VUSU6JRWK=
COLO-668	M{\QUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTZwOESzPFch\|ryP	NXPhOo1qW0GQR1XS
MC116	NHLmNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTZwOUO4PVch\|ryP	NHfnXnBUSU6JRWK=
HCC1937	MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3X2OmlEPTB;Nj65PVI2OSEQvF2=	M1PMXnNCVkeHUh?=
NCI-N87	Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfLWItKUUN3ME23MlE6Ojl\|IN88US=>	NXjtRlFUW0GQR1XS
COLO-320-HSR	NFL5VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfTTWM2OD15LkKyO\|M5KM7:TR?=	MWHTRW5ITVJ?
HCC1806	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M161c2lEPTB;Nz6yOlA1PCEQvF2=	M1i4NnNCVkeHUh?=
OVCAR-3	NXLtUpJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TQVWlEPTB;Nz6zN\|A{QCEQvF2=	M3;1V3NCVkeHUh?=
NUGC-3	NFvOb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHTb2t2UUN3ME23MlM6Pjl2IN88US=>	M4HnV3NCVkeHUh?=
SW1783	M3[4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTdwNEOxO\|Uh\|ryP	MYfTRW5ITVJ?
GCT	M2K5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH21VmVKSzVyPUeuOVY6ODZizszN	NETxe4FUSU6JRWK=
NCI-H2126	NVPhO5RET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTdwN{O2NlUh\|ryP	MkfJV2FPT0WU
MEL-HO	NGfqUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTdwN{ewOVQh\|ryP	M3G2dHNCVkeHUh?=
CAPAN-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1X2[mlEPTB;Nz63O\|M2PyEQvF2=	NIHz[HNUSU6JRWK=
SW756	M4LZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfPTWM2OD15Lke4N\|M{KM7:TR?=	NIK1fpdUSU6JRWK=
SKG-IIIa	MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfvTWM2OD15LkixPFkzKM7:TR?=	Mn;kV2FPT0WU
HCE-T	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnYZmZPUUN3ME23Mlg4Pzh\|IN88US=>	MYXTRW5ITVJ?
Ca-Ski	M2DqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\BTmt[UUN3ME23Mlk6Ozh\|IN88US=>	NYnXcFNoW0GQR1XS
COLO-684	NYrkXIx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILtSldKSzVyPUiuNFE5OThizszN	MmLBV2FPT0WU
KYSE-70	M1nvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDrS3hEUUN3ME24MlA4PzJ7IN88US=>	MnvTV2FPT0WU
TI-73	NWH4fnZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjZbHJDUUN3ME24MlI2QDVzIN88US=>	NFzzVG1USU6JRWK=
BT-20	NIDXfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TEcWlEPTB;OD6yOlA2OiEQvF2=	M4XydXNCVkeHUh?=
MHH-ES-1	M4jKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HIWmlEPTB;OD61NVg{PCEQvF2=	NHy2UZVUSU6JRWK=
TE-12	M4DFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3JTWM2OD16LkW5PVMyKM7:TR?=	NVLmd3NYW0GQR1XS
YH-13	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUW5TGVjUUN3ME24MlYyODB6IN88US=>	NVO3cGp6W0GQR1XS
SF126	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4i1VGlEPTB;OD64N\|g3PSEQvF2=	M2rSZnNCVkeHUh?=
J82	NXrqdIh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4H3cWlEPTB;OD65NFA{QCEQvF2=	NILhUZJUSU6JRWK=
RCC10RGB	MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFn0cXFKSzVyPUiuPVk2PjFizszN	MWfTRW5ITVJ?
SK-UT-1	NGTJdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjxSpFKSzVyPUmuNFQ6PDVizszN	M4iyT3NCVkeHUh?=
LB2241-RCC	MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;aSmlEPTB;OT6xPVE{PyEQvF2=	NFTmXG1USU6JRWK=
LB996-RCC	M37LcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTlwMUm4PUDPxE1?	NV7sVJpyW0GQR1XS
EPLC-272H	M{S2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4X3OmlEPTB;OT6zO\|Y2PyEQvF2=	M1jYVHNCVkeHUh?=
CTV-1	NX62T\|JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXr1Sll[UUN3ME25MlU3PTN{IN88US=>	M4i4enNCVkeHUh?=
HSC-2	NYi3em1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWS4SmttUUN3ME25MlU4PTVizszN	M3T2UnNCVkeHUh?=
SK-MEL-28	NV\3cpFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTlwNkG4PVMh\|ryP	MWPTRW5ITVJ?
MMAC-SF	NV\VdnlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnBV4JtUUN3ME25MlY5PzVizszN	MUfTRW5ITVJ?
CP50-MEL-B	NWjvXlYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nzTmlEPTB;OT63OVc5OiEQvF2=	MUPTRW5ITVJ?
HT-1080	NXi4cVB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITYeFBKSzVyPUmuO\|c4OzlizszN	NITRU41USU6JRWK=
HEC-1	M2PoRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTFyLkOzOVIh\|ryP	M3i1XXNCVkeHUh?=
AGS	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTFyLkO3OEDPxE1?	MV7TRW5ITVJ?
GAMG	NVTrVVFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3[wcGlEPTB;MUCuOVE3OiEQvF2=	MnzuV2FPT0WU
SW48	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnQT\|NwUUN3ME2xNE42OTh7IN88US=>	NGDFTlZUSU6JRWK=
U031	MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn61TWM2OD1zMD61PVA5KM7:TR?=	M4fsdXNCVkeHUh?=
OVCAR-5	NIHDTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTFyLk[0Nlkh\|ryP	NF\qZWhUSU6JRWK=
SF295	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPzNlVwUUN3ME2xNE43PzB2IN88US=>	M3PDWHNCVkeHUh?=
BHT-101	NHPqWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\DU2lEPTB;MUCuO\|E4PyEQvF2=	MnTQV2FPT0WU
VMRC-RCZ	M1ewfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PmPWlEPTB;MUGuN\|IxOSEQvF2=	MmrRV2FPT0WU
ACHN	NIPwVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXK1NVJoUUN3ME2xNU41OjFzIN88US=>	NVLWU4ZUW0GQR1XS
NCI-H526	M{jx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHScohuUUN3ME2xNU42ODR\|IN88US=>	MVLTRW5ITVJ?
MN-60	NIHpbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXKR41KSzVyPUGxMlU{QSEQvF2=	NXn2TWVkW0GQR1XS
NCI-H2291	NX76SpZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTkbllqUUN3ME2xNU42PDZ4IN88US=>	M1P6ZXNCVkeHUh?=
SCC-25	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvnUJd3UUN3ME2xNU44PTV4IN88US=>	NHS0UmJUSU6JRWK=
SK-MEL-2	NV\yTpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1z3N2lEPTB;MUGuO\|Y{PyEQvF2=	NHfDPZRUSU6JRWK=
SN12C	NHjOOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXhTWM2OD1zMT65N\|U2KM7:TR?=	NX[xV3VzW0GQR1XS
NCI-H69	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2WzOGlEPTB;MUKuOFI{PCEQvF2=	NWPOOnFHW0GQR1XS
ME-180	NFjyR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\qTWM2OD1zMj63NFU1KM7:TR?=	NXPnW4l[W0GQR1XS
MC-IXC	M4nIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\xT2lEPTB;MUKuO\|UyQCEQvF2=	MYfTRW5ITVJ?
NCI-H2347	MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfqTWM2OD1zMj63OlE1KM7:TR?=	NU\xfZB5W0GQR1XS
M059J	MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnPPHJEUUN3ME2xNk44PzJ5IN88US=>	NYTJeHpsW0GQR1XS
A2058	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrZPWtKSzVyPUGyMlg3QDFizszN	M{D5bXNCVkeHUh?=
VA-ES-BJ	NIPnPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIOwOHZKSzVyPUGyMlg4QDVizszN	MYrTRW5ITVJ?
Ca9-22	NWS0eolXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTu[IVKSzVyPUGyMlk1PTFizszN	MX7TRW5ITVJ?
KNS-42	M2nSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrmW2pHUUN3ME2xNk46QTh2IN88US=>	M4LWNnNCVkeHUh?=
LoVo	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFf4boRKSzVyPUGzMlI{OTNizszN	NE\ES2lUSU6JRWK=
AM-38	NV7yO3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnqwTWM2OD1zMz6yOVY3KM7:TR?=	MWfTRW5ITVJ?
NB5	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTF\|LkO3OVIh\|ryP	NHX1OnlUSU6JRWK=
L-363	NI\3d2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PBSmlEPTB;MUOuOFA{OyEQvF2=	Mmn2V2FPT0WU
SK-MEL-30	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rJNWlEPTB;MUSuNFY1PSEQvF2=	M4HxZXNCVkeHUh?=
NCI-H1563	NGHRdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4q0eGlEPTB;MUSuOlA{QSEQvF2=	Mnn6V2FPT0WU
NCI-H2228	MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTF2Lk[wO\|ch\|ryP	NEfCfnpUSU6JRWK=
MFM-223	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPtTWM2OD1zNT6xPFE{KM7:TR?=	NWrOXFNYW0GQR1XS
LB831-BLC	NGfDVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7sfmVKSzVyPUG1MlI4PjdizszN	MnT2V2FPT0WU
SW872	MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTF3LkOwPFYh\|ryP	NUnFN3piW0GQR1XS
NCI-H522	MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlO3TWM2OD1zNT6zN\|A3KM7:TR?=	MofBV2FPT0WU
EW-1	M1ftOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPj[GxKSzVyPUG1MlU1PjJizszN	M2TE[3NCVkeHUh?=
HN	NIewd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\tdGlEPTB;MUWuOVk1OiEQvF2=	NGXIU45USU6JRWK=
SW837	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7aPHdqUUN3ME2xOU44QDR5IN88US=>	NWPBfJhlW0GQR1XS
SCC-9	NFPmdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXxOoxkUUN3ME2xOU45OTF2IN88US=>	M3P6XHNCVkeHUh?=
MKN7	MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGntbFNKSzVyPUG1Mlk4OzJizszN	NIr0TYZUSU6JRWK=
KYSE-410	NXjwPI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2f3bWlEPTB;MU[uOVkyKM7:TR?=	MmXPV2FPT0WU
SK-N-DZ	M1PwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTF4Lk[xNVYh\|ryP	MWPTRW5ITVJ?
COR-L105	NIfze21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTF4Lk[1Nlgh\|ryP	NIr5XpVUSU6JRWK=
LB2518-MEL	NGOzdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTF4LkizPFkh\|ryP	NF60NHFUSU6JRWK=
OVCAR-4	NVr4RZRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DCeGlEPTB;MU[uPFg3OiEQvF2=	NIfVPFFUSU6JRWK=
TK10	Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPTe2ZKSzVyPUG2Mlk1PzNizszN	M1rSfXNCVkeHUh?=
KNS-62	NU[wV2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWj1THYyUUN3ME2xOk46Pzd5IN88US=>	M1LmPHNCVkeHUh?=
RPMI-8866	MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXzOmZKSzVyPUG3MlE4OzJizszN	NUj1eFdoW0GQR1XS
HuP-T4	MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIW4SpZKSzVyPUG3MlI1QTVizszN	MliyV2FPT0WU
CGTH-W-1	M3XBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[xTWM2OD1zNz61NlE6KM7:TR?=	M1juZ3NCVkeHUh?=
T-24	M3\CUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLiTWM2OD1zNz61N\|Q4KM7:TR?=	M4T2PXNCVkeHUh?=
HT-3	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rWU2lEPTB;MUeuOVkyPCEQvF2=	M4\IU3NCVkeHUh?=
KS-1	MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfq[4ZKSzVyPUG3MlY4OyEQvF2=	MlGyV2FPT0WU
NCI-H1792	M1L1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTF5Lke5PEDPxE1?	MW\TRW5ITVJ?
ABC-1	NFyyZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX6TWM2OD1zNz64NVQyKM7:TR?=	NFW3WmRUSU6JRWK=
BPH-1	NFK1VGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\ncWlEPTB;MUiuNVY5PSEQvF2=	M1SwdHNCVkeHUh?=
A431	NH7G[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3BTWM2OD1zOD60NVI4KM7:TR?=	MV3TRW5ITVJ?
T98G	M1ixb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzaV4JKSzVyPUG4MlUyPTdizszN	MWXTRW5ITVJ?
BHY	M{m1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTF6Lki2PUDPxE1?	M3XYeHNCVkeHUh?=
Capan-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLJSWpKSzVyPUG4MlkxPzhizszN	NF;kW4tUSU6JRWK=
MDA-MB-175-VII	NIHmNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3OcY4xUUN3ME2xPE46OjB7IN88US=>	MnvvV2FPT0WU
CAL-27	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTF7LkC0PFch\|ryP	MnvwV2FPT0WU
AsPC-1	NUizeY56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4P2TWlEPTB;MUmuPFY2PyEQvF2=	MULTRW5ITVJ?
KU812	NEf4V3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWH2cHdbUUN3ME2xPU46PTd\|IN88US=>	NVrBOoJzW0GQR1XS
NCI-H441	NYX6e\|d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTlV5VKSzVyPUKwMlAxOSEQvF2=	NUG0U2RbW0GQR1XS
Mewo	NVnPTJBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTJyLkGyPFgh\|ryP	M1HsV3NCVkeHUh?=
SK-MEL-24	NYDpNXg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHS1SmJKSzVyPUKwMlE1PzdizszN	NGOzNnFUSU6JRWK=
NCI-H727	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFH2TVBKSzVyPUKwMlI4ODRizszN	MnnrV2FPT0WU
EKVX	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTJyLk[wOkDPxE1?	NVPyTJM6W0GQR1XS
RT-112	Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nvRmlEPTB;MkCuOlEzOiEQvF2=	Ml7XV2FPT0WU
CAMA-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjyTWM2OD1{MD65PFA{KM7:TR?=	NVL2OG9HW0GQR1XS
SW900	M2e5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnL[ZNKSzVyPUKxMlAyPDlizszN	MV\TRW5ITVJ?
NCI-H23	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4m1dGlEPTB;MkGuNVI4PyEQvF2=	NXrjTHJsW0GQR1XS
SK-PN-DW	MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTrSFdKSzVyPUKxMlE3PDlizszN	NYXpOZZjW0GQR1XS
BB30-HNC	NFzFOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnEOWNKSzVyPUKxMlI4PDVizszN	M{PTUXNCVkeHUh?=
VM-CUB-1	NXX1WFk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;Z[255UUN3ME2yNU4{PTN4IN88US=>	NE\rXXFUSU6JRWK=
IST-MEL1	M2W5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLBTWM2OD1{MT6zOlkzKM7:TR?=	NISzeGpUSU6JRWK=
CTB-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHWTWM2OD1{MT60O\|U2KM7:TR?=	MYDTRW5ITVJ?
LCLC-103H	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTJ{LkG1PFIh\|ryP	MVzTRW5ITVJ?
PANC-03-27	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rpcmlEPTB;MkKuOVE3QSEQvF2=	MoK2V2FPT0WU
HTC-C3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnGb\|RKSzVyPUKyMlU2PTVizszN	NFTjWGdUSU6JRWK=
TE-8	MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTJ\|LkK1OlUh\|ryP	NYPoeGNIW0GQR1XS
NCI-H292	MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Tj[2lEPTB;MkWuN\|U{PiEQvF2=	NE[3bGRUSU6JRWK=
COLO-680N	NG\SbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnRTWM2OD1{NT62N\|I6KM7:TR?=	MYrTRW5ITVJ?
KYSE-520	MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7BNGtKSzVyPUK1MlY1PCEQvF2=	MXTTRW5ITVJ?
NB10	NWPteIxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlP4TWM2OD1{Nj6zNVE4KM7:TR?=	NF3mbnVUSU6JRWK=
NCI-H661	MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzJTWM2OD1{Nj60O\|E{KM7:TR?=	MVPTRW5ITVJ?
GMS-10	M2nCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;rVWlEPTB;Mk[uPFY{QCEQvF2=	NF;HZmlUSU6JRWK=
NCI-H2122	NU\oeXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfxTWM2OD1{Nj65PVk5KM7:TR?=	M{L0SnNCVkeHUh?=
OVCAR-8	M2XmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXQTWM2OD1{Nz6wOlM5KM7:TR?=	MV;TRW5ITVJ?
DJM-1	NGnBZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPLTWM2OD1{Nz6xOFU1KM7:TR?=	NE\PWZdUSU6JRWK=
UACC-893	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PyW2lEPTB;MkeuPVg4QCEQvF2=	MmO3V2FPT0WU
C8166	MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoO4TWM2OD1{OD62PVM5KM7:TR?=	NVTuPY84W0GQR1XS
NCI-H1693	MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3hOpdNUUN3ME2yPE43QTd3IN88US=>	NULOWoRwW0GQR1XS
TYK-nu	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHDd\|VKSzVyPUOwMlA{PDVizszN	MV;TRW5ITVJ?
SW1710	NFvjWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;zVWlEPTB;M{CuNVI3KM7:TR?=	MYjTRW5ITVJ?
A375	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILRZnJKSzVyPUOwMlMzPDNizszN	MXPTRW5ITVJ?
HMV-II	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTZTWM2OD1\|MT6zOVkzKM7:TR?=	MVLTRW5ITVJ?
NCI-H2087	NYTPeJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Hte2lEPTB;M{GuOlM2OiEQvF2=	NFOyXpJUSU6JRWK=
CAL-54	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkj5TWM2OD1\|MT63NlQyKM7:TR?=	NF7i[YRUSU6JRWK=
HCC70	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTN{LkGzPFch\|ryP	NFfpN3lUSU6JRWK=
ES1	NVzyN5VuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj1SXVCUUN3ME2zNk4{ODZ{IN88US=>	MWrTRW5ITVJ?
NCI-H1355	MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXWTWM2OD1\|Mz6yNFQh\|ryP	M{PobXNCVkeHUh?=
CFPAC-1	M3ixfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\uTWM2OD1\|Mz6yN\|MzKM7:TR?=	MlfIV2FPT0WU
MKN28	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFWyWJFKSzVyPUOzMlM5ODlizszN	M3r0WnNCVkeHUh?=
HDLM-2	NHzJWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPHeVhKSzVyPUOzMlY6OzFizszN	MYHTRW5ITVJ?
PANC-10-05	M2HRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrUZ\|k6UUN3ME2zOE4yODF2IN88US=>	Ml25V2FPT0WU
SAS	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj3Xo5KSzVyPUO0MlQ2PjVizszN	NUD4O2w4W0GQR1XS
HCC1395	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmf3TWM2OD1\|ND63NVg3KM7:TR?=	Ml\lV2FPT0WU
8305C	M1PqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrYTWM2OD1\|NT64OFE2KM7:TR?=	NFvrOmZUSU6JRWK=
KM12	NXLoOFhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jkbmlEPTB;M{[uO\|U1PyEQvF2=	MlfEV2FPT0WU
SW1116	NUTGRppRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXUTWM2OD1\|Nz61PVkzKM7:TR?=	NFe3T2NUSU6JRWK=
SK-MEL-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTSTWM2OD1\|OD6zN\|g6KM7:TR?=	MYfTRW5ITVJ?
HCC2218	M2X1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHyeYJ2UUN3ME2zPE43PTF7IN88US=>	Mm\xV2FPT0WU
T84	Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4j4RWlEPTB;M{iuO\|QxQSEQvF2=	MXLTRW5ITVJ?
ETK-1	NV;mbos2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M121XmlEPTB;M{muNFIzKM7:TR?=	MVvTRW5ITVJ?
COLO-800	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELOZ3VKSzVyPUO5MlM5PjhizszN	NUjabHMyW0GQR1XS
CAL-12T	M3W5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTxTWM2OD1\|OT61NlgyKM7:TR?=	MV7TRW5ITVJ?
ACN	MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NISydVBKSzVyPUSwMlQ6OTFizszN	MmfaV2FPT0WU
SJSA-1	NETPemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXmOHlKSzVyPUSxMlE2QTZizszN	MnfWV2FPT0WU
PSN1	Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonYTWM2OD12MT6xO\|Q6KM7:TR?=	MWnTRW5ITVJ?
D-566MG	NVfIeGNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrtPGxwUUN3ME20NU4zODh4IN88US=>	MkXqV2FPT0WU
EGI-1	NG[2SplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTR{LkSyPEDPxE1?	NXrPUItoW0GQR1XS
A204	NXH4TZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTR{Lk[zPFgh\|ryP	M2HzSXNCVkeHUh?=
Saos-2	M4D2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTR{LkizOlkh\|ryP	NYDZfJY{W0GQR1XS
SNU-C2B	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDxe2xIUUN3ME20N{43QDd6IN88US=>	NXXyTVFjW0GQR1XS
HLE	NV\PSWQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGq2V3NKSzVyPUS0MlA5PTZizszN	MonhV2FPT0WU
SW1463	NFTQV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPR[VlKSzVyPUS0Mlk6PzFizszN	MXTTRW5ITVJ?
DSH1	NV;ONVR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTR3LkCwN\|Mh\|ryP	NV3tV5Z2W0GQR1XS
MCF7	M13R[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXCTWM2OD12NT61NFUyKM7:TR?=	NIfIUZBUSU6JRWK=
K5	MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\ndmlEPTB;NEWuPVQxPSEQvF2=	NYPLdpZHW0GQR1XS
NCI-H358	M4XEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HPeGlEPTB;NEeuNlE2KM7:TR?=	MWjTRW5ITVJ?
NCI-H2030	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTR5LkKzO\|Qh\|ryP	NHSzdVdUSU6JRWK=
SW948	NULVWIJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{K3SWlEPTB;NEeuOFY1KM7:TR?=	M3;lSHNCVkeHUh?=
BALL-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTR5Lk[xOlgh\|ryP	NUfWeplVW0GQR1XS
TE-9	MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPjU2VKSzVyPUS3Mlk2QDFizszN	MlXqV2FPT0WU
SK-N-FI	Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTR6LkCzOVgh\|ryP	MYnTRW5ITVJ?
KALS-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnP0TWM2OD12OD6xNlg6KM7:TR?=	NIryeWVUSU6JRWK=
HO-1-N-1	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTR6Lke0OFUh\|ryP	NGrwS5FUSU6JRWK=
NCI-H2452	NWjFUm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTR7LkGxOVIh\|ryP	NVXmb2FvW0GQR1XS
OC-314	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGe1WlFKSzVyPUS5MlY5OzRizszN	NFzQWGZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	+ Expand Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	+ Expand Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03366103	Recruiting	Metastatic Malignant Solid Neoplasm\|Recurrent Malignant Solid Neoplasm\|Recurrent Small Cell Lung Carcinoma\|Stage III Small Cell Lung Carcinoma AJCC v7\|Stage IIIA Small Cell Lung Carcinoma AJCC v7\|Stage IIIB Small Cell Lung Carcinoma AJCC v7\|Stage IV Lung Small Cell Carcinoma AJCC v7\|Unresectable Solid Neoplasm	National Cancer Institute (NCI)	November 29 2017	Phase 1\|Phase 2
NCT03181126	Recruiting	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT03366103	Recruiting	Metastatic Malignant Solid Neoplasm\|Recurrent Malignant Solid Neoplasm\|Recurrent Small Cell Lung Carcinoma\|Stage III Small Cell Lung Carcinoma AJCC v7\|Stage IIIA Small Cell Lung Carcinoma AJCC v7\|Stage IIIB Small Cell Lung Carcinoma AJCC v7\|Stage IV Lung Small Cell Carcinoma AJCC v7\|Unresectable Solid Neoplasm	National Cancer Institute (NCI)	November 29 2017	Phase 1\|Phase 2
NCT03181126	Recruiting	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT03222609	Recruiting	Myelofibrosis (MF)	AbbVie	October 31 2017	Phase 2
NCT03222609	Recruiting	Myelofibrosis (MF)	AbbVie	October 31 2017	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 43 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 43 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)